Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-06-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
创业板向不特定对象发行可转换公司债券募集说明书（申报稿）（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书（申报稿）" which translates to "Offering Prospectus (Draft)" for a convertible bond issuance by 云南沃森生物技术股份有限公司. It contains detailed information about the bond issuance, credit rating, profit distribution policies, risk factors, and management commitments related to the convertible bond offering. The document is not an annual report, earnings release, or management discussion but a detailed offering prospectus for a capital raising activity. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains substantive content about the financing offering, not just an announcement or a brief summary. Therefore, the correct classification is CAP with high confidence.
2023-06-28 Chinese
关于云南沃森生物技术股份有限公司申请向不特定对象发行可转换公司债券的审核问询函的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response to a regulatory inquiry letter from the Shenzhen Stock Exchange regarding the company's application to issue convertible bonds to unspecified investors. It contains extensive information about the company's projects, licenses, approvals, and compliance with regulatory requirements. The content is focused on regulatory compliance, project descriptions, and legal and operational qualifications related to the bond issuance. It is not a financial report, earnings release, or management discussion, nor is it a simple announcement or presentation. The document is a formal regulatory filing responding to a regulatory authority's inquiry, which fits the category of Regulatory Filings (RNS).
2023-06-28 Chinese
创业板向不特定对象发行可转换公司债券之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" which translates to "Issuance Sponsorship Letter" or "Sponsorship Document" related to the issuance of convertible bonds by Yunnan Walvax Biotechnology Co., Ltd. It is addressed to the China Securities Regulatory Commission and Shenzhen Stock Exchange, indicating a regulatory filing related to securities issuance. The document contains detailed information about the issuance, the sponsor institution, legal compliance, financial data, shareholder structure, and internal review procedures. It is a comprehensive document supporting the issuance of convertible bonds to unspecified investors on the Growth Enterprise Market (创业板). This type of document is a formal sponsorship letter required by regulatory authorities for securities issuance, not a financial report like an annual or interim report, nor an earnings release or presentation. It is also not a simple announcement or certification but a detailed regulatory filing related to capital raising. Therefore, the document best fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full filing, not just an announcement or summary.
2023-06-28 Chinese
创业板向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled '上市保荐书' which translates to 'Listing Sponsorship Letter' or 'Sponsorship Document' related to the issuance of convertible bonds by Yunnan Walvax Biotechnology Co., Ltd. It contains detailed financial data, company background, business operations, R&D information, and risk factors. The document is a formal sponsorship letter prepared by the underwriting institution for the issuance and listing of convertible bonds on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It is not an annual report, earnings release, or a regulatory filing per se, but a detailed document supporting a capital market transaction (issuance of convertible bonds). This type of document is best classified under Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes. The document length is substantial (15,000 characters), and it contains substantive financial and business information related to the financing event, not just an announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2023-06-28 Chinese
关于申请向不特定对象发行可转换公司债劵的审核问询函回复及募集说明书等申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application to issue convertible bonds to unspecified investors. It includes references to regulatory review by the Shenzhen Stock Exchange and the China Securities Regulatory Commission, and mentions the submission of related application documents and responses to inquiry letters. The document does not contain actual financial statements or detailed financial data but rather updates on the financing application process and regulatory review status. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report but providing substantive update on financing activities.
2023-06-28 Chinese
大信会计师事务所（特殊普通合伙）关于云南沃森生物技术股份有限公司申请向不特定对象发行可转换公司债券的审核问询函的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shenzhen Stock Exchange regarding a company's application to issue convertible bonds to unspecified investors. It contains extensive financial and operational details about the use of proceeds, capitalized expenditures, project descriptions, and compliance with securities regulations. The content focuses on the company's capital raising activities, specifically the issuance of convertible bonds and the allocation of the raised funds to various projects and working capital. This aligns with the category of Capital/Financing Update filings, which cover updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and project details, not merely an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-06-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.